Abstract:Abstract Kaposi sarcoma (KS) in organ transplant recipients (OTRs) is usually due to reactivation of latent human herpes virus (HHV)-8 and is therefore seen mainly in patients from countries with a high seroprevalence of HHV-8. Far fewer cases are due to HHV-8 acquired post-transplant or donor-transmitted. Since mid-2023, NHS Blood-and-Transplant (NHS-BT) has screened donor HHV-8 serology. However, there are no recommendations for screening recipients or transplant candidates. In addition, more sensitive serology testing is not routinely available, and most centres rely on HHV-8 DNA assays. In this study, we describe clinicopathological features of OTR-KS diagnosed between 2018 and 2023 in our centre and highlight an urgent need for improved HHV-8 screening of high-risk patient groups. We reviewed clinicopathological features of OTR-KS diagnosed between January 2018 and January 2023. In total, 11 OTRs had biopsy-proven KS. The median age was 53 years range (36–69) and the median time from transplant to patient-reported onset of KS lesions was 7.5 months. Ten of 11 patients (91%) were born in sub-Saharan Africa. One patient was HIV positive. Cutaneous KS was present in all patients, there was lymph-node involvement in 5 of 11 patients (45%) and visceral involvement in 2 of 11 (18%). Serum HHV-8 DNA was positive in 9 of 11 patients (81%), although in 4 of 8 patients (50%) this was negative on at least one occasion; in 2 of 11 patients it was never positive. Viral loads did not clearly correlate with disease activity. No donors were HHV-8 positive where this information was available. The most common initial treatment intervention was modification of immunosuppression; mycophenolate mofetil was stopped in 10 of 10 patients and/or calcineurin inhibitors were switched to sirolimus in 8 of 10 OTRs. In 10 of 11 patients (91%) this was sufficient to control KS. Only one OTR required chemotherapy. Graft loss occurred in 4 of 11 cases (36%). One patient died shortly after return to dialysis following chemotherapy. We have previously published data on 16 cases of OTR-KS diagnosed in our centre between 1989 and 2018. The current series of 11 cases over the past 5 years represents a significant increase and is likely to reflect, in large part, the changing demographics of our patient population. We have demonstrated that diagnostic and predictive use of HHV-8 DNA testing has limitations: 6 of 11 patients (54%) had one or more negative tests despite positive HHV-8 immunohistochemistry on skin biopsy. Although NHS-BT now routinely screens all donors, our data highlight a significant need for routine recipient testing. We propose that routine pre/post-transplant screening with improved HHV-8 assays should be introduced, at least in patient populations at risk of latent HHV-8. Such screening has potential to allow optimized post-transplant management of HHV-8 positive OTRs and ultimately improve outcomes in OTR-KS.

Burden and frequency of viral testing of kidney and non-kidney transplant recipients

Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative

Viral cultures, cycle threshold values and viral load estimation for assessing SARS-CoV-2 infectiousness in haematopoietic stem cell and solid organ transplant patients: a systematic review

Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients

Viral load kinetics and the clinical consequences of cytomegalovirus in kidney transplantation

Atypical pneumonia testing in transplant recipients

Nationwide survey of infection prevention protocols in solid organ transplantation in South Korea

Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients

Clinical utility of immune function based on IFN-γ monitoring of lymphocyte subsets for parvovirus B19 infection in renal recipients

BI06 The rising incidence of post-transplant Kaposi sarcoma in organ transplant recipients in a single-centre cohort: should we be routinely screening?

Diagnosis, Prevention, and Treatment of Infections in Kidney Transplantation

Impact of induction agents and maintenance immunosuppression on torque teno virus loads and year-one complications after kidney transplantation

Utility of Serial Microbial Cell-free DNA Sequencing for Inpatient and Outpatient Pathogen Surveillance Among Allogeneic Hematopoietic Stem Cell Transplant Recipients

Serologic evaluation of vaccine preventable infections and vaccination rates in kidney transplant candidates

Performance of the cobas EBV and cobas BKV assays: multi-site comparison of standardized quantitation

Pre-Transplantation Strategies for Infectious Disease Mitigation and Prevention

Cytomegalovirus Post-Prophylaxis Surveillance in High-Risk Kidney and Liver Recipients Prevents CMV End-Organ Disease and Ganciclovir-Resistance

Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: Retrospective analysis of disease transmission and safety

Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus

The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience

The Burden and Impact of Early Post-Transplant Multidrug-resistant Organism Detection Among Renal Transplant Recipients, 2005-2021